Top

Reviews in Endocrine and Metabolic Disorders

Published in:

01-12-2017

Neuroendocrine neoplasms – still a challenge despite major advances in clinical care with the development of specialized guidelines

Authors: Stephan Petersenn, Christian A. Koch

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 4/2017

Excerpt

The term ‘neuroendocrine neoplasms’ (NEN) covers a wide range of tumors originating from neuroendocrine cells in various organs. Heterogeneity and rarity of NEN have hampered early diagnosis and standardized treatment for years, with many physicians being unaware of the clinical relevance of NEN. Although expanding knowledge of the molecular characteristics of neuroendocrine cells resulted in new diagnostic and therapeutic possibilities, their integration into management algorithms is still ongoing. Furthermore, availability of diagnostic and therapeutic tools varies considerably in different regions of the world. …

Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology. 2004;80(6):394–424. https://doi.org/10.1159/000085237.CrossRefPubMed

Jensen RT, Niederle B, Mitry E, Ramage JK, Steinmuller T, Lewington V, et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology. 2006;84(3):173–82. https://doi.org/10.1159/000098009.CrossRefPubMed

de Herder WW, Niederle B, Scoazec JY, Pauwels S, Kloppel G, Falconi M, et al. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology. 2006;84(3):183–8. https://doi.org/10.1159/000098010.CrossRefPubMed

O'Toole D, Salazar R, Falconi M, Kaltsas G, Couvelard A, de Herder WW, et al. Rare functioning pancreatic endocrine tumors. Neuroendocrinology. 2006;84(3):189–95. https://doi.org/10.1159/000098011.CrossRefPubMed

Falconi M, Plockinger U, Kwekkeboom DJ, Manfredi R, Korner M, Kvols L, et al. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology. 2006;84(3):196–211. https://doi.org/10.1159/000098012.CrossRefPubMed

Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95(2):98–119. https://doi.org/10.1159/000335591.CrossRefPubMedPubMedCentral

Falconi M, Bartsch DK, Eriksson B, Kloppel G, Lopes JM, O'Connor JM, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology. 2012;95(2):120–34. https://doi.org/10.1159/000335587.CrossRefPubMed

Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153–71. https://doi.org/10.1159/000443171.CrossRefPubMedPubMedCentral

Jensen RT, Rindi G, Arnold R, Lopes JM, Brandi ML, Bechstein WO, et al. Well-differentiated duodenal tumor/carcinoma (excluding gastrinomas). Neuroendocrinology. 2006;84(3):165–72. https://doi.org/10.1159/000098008.CrossRefPubMed

10.

Ruszniewski P, Delle Fave G, Cadiot G, Komminoth P, Chung D, Kos-Kudla B, et al. Well-differentiated gastric tumors/carcinomas. Neuroendocrinology. 2006;84(3):158–64. https://doi.org/10.1159/000098007.CrossRefPubMed

11.

Delle Fave G, Kwekkeboom DJ, Van Cutsem E, Rindi G, Kos-Kudla B, Knigge U, et al. ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology. 2012;95(2):74–87. https://doi.org/10.1159/000335595.CrossRefPubMed

12.

Delle Fave G, O'Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, et al. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):119–24. https://doi.org/10.1159/000443168.CrossRefPubMed

13.

Eriksson B, Kloppel G, Krenning E, Ahlman H, Plockinger U, Wiedenmann B, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors--well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology. 2008;87(1):8–19. https://doi.org/10.1159/000111034.CrossRefPubMed

14.

Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, Knigge U, et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology. 2016;103(2):125–38. https://doi.org/10.1159/000443170.CrossRefPubMed

15.

Plockinger U, Couvelard A, Falconi M, Sundin A, Salazar R, Christ E, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology. 2008;87(1):20–30. https://doi.org/10.1159/000109876.CrossRefPubMed

16.

Pape UF, Perren A, Niederle B, Gross D, Gress T, Costa F, et al. ENETS consensus guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology. 2012;95(2):135–56. https://doi.org/10.1159/000335629.CrossRefPubMed

17.

Pape UF, Niederle B, Costa F, Gross D, Kelestimur F, Kianmanesh R, et al. ENETS consensus guidelines for neuroendocrine neoplasms of the appendix (excluding goblet cell carcinomas). Neuroendocrinology. 2016;103(2):144–52. https://doi.org/10.1159/000443165.CrossRefPubMed

18.

Ramage JK, Goretzki PE, Manfredi R, Komminoth P, Ferone D, Hyrdel R, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. Neuroendocrinology. 2008;87(1):31–9. https://doi.org/10.1159/000111036.CrossRefPubMed

19.

Caplin M, Sundin A, Nillson O, Baum RP, Klose KJ, Kelestimur F, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology. 2012;95(2):88–97. https://doi.org/10.1159/000335594.CrossRefPubMed

20.

Ramage JK, De Herder WW, Delle Fave G, Ferolla P, Ferone D, Ito T, et al. ENETS consensus guidelines update for colorectal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):139–43. https://doi.org/10.1159/000443166.CrossRefPubMed

21.

Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, et al. Pulmonary neuroendocrine (carcinoid) tumors: European neuroendocrine tumor society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26(8):1604–20. https://doi.org/10.1093/annonc/mdv041.CrossRefPubMed

22.

Steinmuller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ, et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2008;87(1):47–62. https://doi.org/10.1159/000111037.CrossRefPubMed

23.

Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157–76. https://doi.org/10.1159/000335597.CrossRefPubMed

24.

Pavel M, O'Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, et al. ENETS consensus guidelines update for the Management of Distant Metastatic Disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172–85. https://doi.org/10.1159/000443167.CrossRefPubMed

25.

Pavel M, Grossman A, Arnold R, Perren A, Kaltsas G, Steinmuller T, et al. ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors. Neuroendocrinology. 2010;91(4):326–32. https://doi.org/10.1159/000287277.CrossRefPubMed

26.

Kos-Kudla B, O'Toole D, Falconi M, Gross D, Kloppel G, Sundin A, et al. ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors. Neuroendocrinology. 2010;91(4):341–50. https://doi.org/10.1159/000287255.CrossRefPubMed

27.

Kianmanesh R, Ruszniewski P, Rindi G, Kwekkeboom D, Pape UF, Kulke M, et al. ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors. Neuroendocrinology. 2010;91(4):333–40. https://doi.org/10.1159/000286700.CrossRefPubMed

28.

Nilsson O, Van Cutsem E, Delle Fave G, Yao JC, Pavel ME, McNicol AM, et al. Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology. 2006;84(3):212–5. https://doi.org/10.1159/000098013.CrossRefPubMed

29.

Ahlman H, Nilsson O, McNicol AM, Ruszniewski P, Niederle B, Ricke J, et al. Poorly-differentiated endocrine carcinomas of midgut and hindgut origin. Neuroendocrinology. 2008;87(1):40–6. https://doi.org/10.1159/000109976.CrossRefPubMed

30.

Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016;103(2):186–94. https://doi.org/10.1159/000443172.CrossRefPubMed

31.

Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449(4):395–401. https://doi.org/10.1007/s00428-006-0250-1.CrossRefPubMedPubMedCentral

32.

Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451(4):757–62. https://doi.org/10.1007/s00428-007-0452-1.CrossRefPubMed

33.

Kloppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2009;90(2):162–6. https://doi.org/10.1159/000182196.CrossRefPubMed

34.

Perren A, Couvelard A, Scoazec JY, Costa F, Borbath I, Delle Fave G, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pathology: diagnosis and prognostic stratification. Neuroendocrinology. 2017;105(3):196–200. https://doi.org/10.1159/000457956.CrossRefPubMed

35.

O'Toole D, Grossman A, Gross D, Delle Fave G, Barkmanova J, O'Connor J, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biochemical markers. Neuroendocrinology. 2009;90(2):194–202. https://doi.org/10.1159/000225948.CrossRefPubMed

36.

Oberg K, Couvelard A, Delle Fave G, Gross D, Grossman A, Jensen RT, et al. ENETS consensus guidelines for standard of care in neuroendocrine tumours: biochemical markers. Neuroendocrinology. 2017;105(3):201–11. https://doi.org/10.1159/000472254.CrossRefPubMed

37.

Sundin A, Vullierme MP, Kaltsas G, Plockinger U, Mallorca Consensus Conference p, European neuroendocrine tumor S. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological examinations. Neuroendocrinology. 2009;90(2):167–83. https://doi.org/10.1159/000184855.CrossRefPubMed

38.

Kwekkeboom DJ, Krenning EP, Scheidhauer K, Lewington V, Lebtahi R, Grossman A, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: somatostatin receptor imaging with (111)in-pentetreotide. Neuroendocrinology. 2009;90(2):184–9. https://doi.org/10.1159/000225946.CrossRefPubMed

39.

Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, Nuclear Medicine & Hybrid Imaging. Neuroendocrinology. 2017;105(3):212–44. https://doi.org/10.1159/000471879.CrossRefPubMed

40.

Plockinger U, Gustafsson B, Ivan D, Szpak W, Davar J, Conference p MC, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: echocardiography. Neuroendocrinology. 2009;90(2):190–3. https://doi.org/10.1159/000225947.CrossRefPubMed

41.

Partelli S, Bartsch DK, Capdevila J, Chen J, Knigge U, Niederle B, et al. ENETS consensus guidelines for standard of care in neuroendocrine tumours: surgery for small intestinal and pancreatic neuroendocrine tumours. Neuroendocrinology. 2017;105(3):255–65. https://doi.org/10.1159/000464292.CrossRefPubMed

42.

Akerstrom G, Falconi M, Kianmanesh R, Ruszniewski P, Plockinger U, Mallorca Consensus Conference p, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pre- and perioperative therapy in patients with neuroendocrine tumors. Neuroendocrinology. 2009;90(2):203–8. https://doi.org/10.1159/000225949.CrossRefPubMed

43.

Kaltsas G, Caplin M, Davies P, Ferone D, Garcia-Carbonero R, Grozinsky-Glasberg S, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pre- and perioperative therapy in patients with neuroendocrine tumors. Neuroendocrinology. 2017;105(3):245–54. https://doi.org/10.1159/000461583.CrossRefPubMedPubMedCentral

44.

Oberg K, Ferone D, Kaltsas G, Knigge UP, Taal B, Plockinger U, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biotherapy. Neuroendocrinology. 2009;90(2):209–13. https://doi.org/10.1159/000183751.CrossRefPubMed

45.

Pavel M, Valle JW, Eriksson B, Rinke A, Caplin M, Chen J, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: systemic therapy - biotherapy and novel targeted agents. Neuroendocrinology. 2017;105(3):266–80. https://doi.org/10.1159/000471880.CrossRefPubMed

46.

Kwekkeboom DJ, Krenning EP, Lebtahi R, Komminoth P, Kos-Kudla B, de Herder WW, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology. 2009;90(2):220–6. https://doi.org/10.1159/000225951.CrossRefPubMed

47.

Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues. Neuroendocrinology. 2017;105(3):295–309. https://doi.org/10.1159/000475526.CrossRefPubMed

48.

Eriksson B, Annibale B, Bajetta E, Mitry E, Pavel M, Platania M, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology. 2009;90(2):214–9. https://doi.org/10.1159/000225950.CrossRefPubMed

49.

Garcia-Carbonero R, Rinke A, Valle JW, Fazio N, Caplin M, Gorbounova V, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms. Systemic therapy 2: chemotherapy. Neuroendocrinology. 2017;105(3):281–94. https://doi.org/10.1159/000473892.CrossRefPubMed

50.

Arnold R, Chen YJ, Costa F, Falconi M, Gross D, Grossman AB, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: follow-up and documentation. Neuroendocrinology. 2009;90(2):227–33. https://doi.org/10.1159/000225952.CrossRefPubMed

51.

Knigge U, Capdevila J, Bartsch DK, Baudin E, Falkerby J, Kianmanesh R, et al. ENETS consensus recommendations for the standards of care in neuroendocrine neoplasms: follow-up and documentation. Neuroendocrinology. 2017;105(3):310–9. https://doi.org/10.1159/000458155.CrossRefPubMed

52.

Oberg K, Hellman P, Kwekkeboom D, Jelic S, Group EGW. Neuroendocrine bronchial and thymic tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v220–2. https://doi.org/10.1093/annonc/mdq191.CrossRefPubMed

53.

Oberg K, Akerstrom G, Rindi G, Jelic S, Group EGW. Neuroendocrine gastroenteropancreatic tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v223–7. https://doi.org/10.1093/annonc/mdq192.CrossRefPubMed

54.

Oberg K, Hellman P, Ferolla P, Papotti M, Group EGW. Neuroendocrine bronchial and thymic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii120–3. https://doi.org/10.1093/annonc/mds267.PubMed

55.

Oberg K, Knigge U, Kwekkeboom D, Perren A, Group EGW. Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii124–30. https://doi.org/10.1093/annonc/mds295.PubMed

56.

Committee EG. Appendix 3: neuroendocrine tumours: eUpdate published online September 2016 (www.esmo.org/Guidelines/Neuroendocrine-Tumours). Ann Oncol 2016;27(suppl 5):v138-v9. https://doi.org/10.1093/annonc/mdw356.

57.

Kvols LK, Brendtro KL; North American Neuroendocrine Tumor Society (NANETS). The North American Neuroendocrine Tumor Society (NANETS) guidelines: mission, goals, and process. Pancreas. 2010;39(6):705–6. https://doi.org/10.1097/MPA.0b013e3181eb7451.

58.

Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39(6):707–12. https://doi.org/10.1097/MPA.0b013e3181ec124e.CrossRefPubMed

59.

Vinik AI, Woltering EA, Warner RR, Caplin M, O'Dorisio TM, Wiseman GA, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010;39(6):713–34. https://doi.org/10.1097/MPA.0b013e3181ebaffd.CrossRefPubMed

60.

Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010;39(6):735–52. https://doi.org/10.1097/MPA.0b013e3181ebb168.CrossRefPubMedPubMedCentral

61.

Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas. 2010;39(6):753–66. https://doi.org/10.1097/MPA.0b013e3181ebb2a5.CrossRefPubMed

62.

Anthony LB, Strosberg JR, Klimstra DS, Maples WJ, O'Dorisio TM, Warner RR, et al. The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum. Pancreas. 2010;39(6):767–74. https://doi.org/10.1097/MPA.0b013e3181ec1261.

63.

Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak K, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39(6):775–83. https://doi.org/10.1097/MPA.0b013e3181ebb4f0.CrossRefPubMedPubMedCentral

64.

Phan AT, Oberg K, Choi J, Harrison LH, Jr., Hassan MM, Strosberg JR et al. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas 2010;39(6):784–798. https://doi.org/10.1097/MPA.0b013e3181ec1380.

65.

Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010;39(6):799–800. https://doi.org/10.1097/MPA.0b013e3181ebb56f.CrossRefPubMedPubMedCentral

66.

Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42(4):557–77. https://doi.org/10.1097/MPA.0b013e31828e34a4.CrossRefPubMedPubMedCentral

67.

Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, et al. The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical Management of Midgut Neuroendocrine Tumors. Pancreas. 2017;46(6):707–14. https://doi.org/10.1097/MPA.0000000000000850.CrossRefPubMed

68.

Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, et al. The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the north American neuroendocrine tumor society. Pancreas. 2017;46(6):715–31. https://doi.org/10.1097/MPA.0000000000000846.CrossRefPubMed

69.

Kos-Kudla B, Blicharz-Dorniak J, Handkiewicz-Junak D, Jarzab B, Jarzab M, Kunikowska J, et al. Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish network of neuroendocrine tumours). Endokrynol Pol. 2013;64(6):418–43. https://doi.org/10.5603/EP.2013.0028.CrossRefPubMed

70.

Rydzewska G, Cichocki A, Cwikla JB, Foltyn W, Hubalewska-Dydejczyk A, Kaminski G, et al. Gastroduodenal neuroendocrine neoplasms including gastrinoma - management guidelines (recommended by the Polish network of neuroendocrine tumours). Endokrynol Pol. 2013;64(6):444–58. https://doi.org/10.5603/EP.2013.0030.CrossRefPubMed

71.

Kos-Kudla B, Hubalewska-Dydejczyk A, Kusnierz K, Lampe P, Marek B, Nasierowska-Guttmejer A, et al. Pancreatic neuroendocrine neoplasms - management guidelines (recommended by the Polish network of neuroendocrine tumours). Endokrynol Pol. 2013;64(6):459–79. https://doi.org/10.5603/EP.2013.0031.CrossRefPubMed

72.

Bolanowski M, Bednarczuk T, Bobek-Billewicz B, Handkiewicz-Junak D, Jeziorski A, Nowakowska-Dulawa E, et al. Neuroendocrine neoplasms of the small intestine and the appendix - management guidelines (recommended by the Polish network of neuroendocrine tumours). Endokrynol Pol. 2013;64(6):480–93. https://doi.org/10.5603/EP.2013.0029.CrossRefPubMed

73.

Starzynska T, Deptala A, Krolicki L, Kunikowska J, Londzin-Olesik M, Nasierowska-Guttmejer A, et al. Colorectal neuroendocrine neoplasms - management guidelines (recommended by the Polish network of neuroendocrine tumours). Endokrynol Pol. 2013;64(6):494–504. https://doi.org/10.5603/EP.2013.0032.CrossRefPubMed

74.

Kos-Kudla B, Blicharz-Dorniak J, Strzelczyk J, Baldys-Waligorska A, Bednarczuk T, Bolanowski M, et al. Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish network of neuroendocrine tumours). Endokrynol Pol. 2017;68(2):79–110. https://doi.org/10.5603/EP.2017.0015.CrossRefPubMed

75.

Lipinski M, Rydzewska G, Foltyn W, Andrysiak-Mamos E, Baldys-Waligorska A, Bednarczuk T, et al. Gastroduodenal neuroendocrine neoplasms, including gastrinoma - management guidelines (recommended by the Polish network of neuroendocrine tumours). Endokrynol Pol. 2017;68(2):138–53. https://doi.org/10.5603/EP.2017.0016.CrossRefPubMed

76.

Kos-Kudla B, Rosiek V, Borowska M, Baldys-Waligorska A, Bednarczuk T, Blicharz-Dorniak J, et al. Pancreatic neuroendocrine neoplasms - management guidelines (recommended by the Polish network of neuroendocrine tumours). Endokrynol Pol. 2017;68(2):169–97. https://doi.org/10.5603/EP.2017.2016.CrossRefPubMed

77.

Bednarczuk T, Bolanowski M, Zemczak A, Baldys-Waligorska A, Blicharz-Dorniak J, Boratyn-Nowicka A, et al. Neuroendocrine neoplasms of the small intestine and appendix - management guidelines (recommended by the Polish network of neuroendocrine tumours). Endokrynol Pol. 2017;68(2):223–36. https://doi.org/10.5603/EP.2017.0018.CrossRefPubMed

78.

Starzynska T, Londzin-Olesik M, Baldys-Waligorska A, Bednarczuk T, Blicharz-Dorniak J, Bolanowski M, et al. Colorectal neuroendocrine neoplasms - management guidelines (recommended by the Polish network of neuroendocrine tumours). Endokrynol Pol. 2017;68(2):250–60. https://doi.org/10.5603/EP.2017.0019.CrossRefPubMed

79.

Oberg K, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncol. 2004;43(7):617–25. https://doi.org/10.1080/02841860410018575.CrossRefPubMed

80.

Oberg K, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types. Acta Oncol. 2004;43(7):626–36. https://doi.org/10.1080/02841860410018584.CrossRefPubMed

81.

Janson ET, Sorbye H, Welin S, Federspiel B, Gronbaek H, Hellman P, et al. Nordic guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol. 2010;49(6):740–56. https://doi.org/10.3109/0284186X.2010.492791.CrossRefPubMed

82.

Janson ET, Sorbye H, Welin S, Federspiel B, Gronbaek H, Hellman P, et al. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol. 2014;53(10):1284–97. https://doi.org/10.3109/0284186X.2014.941999.CrossRefPubMed

83.

Garcia-Carbonero R, Salazar R, Sevilla I, Isla D. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (GEP NETS). Clin Transl Oncol. 2011;13(8):545–51. https://doi.org/10.1007/s12094-011-0695-9.CrossRefPubMed

84.

Garcia-Carbonero R, Vilardell F, Jimenez-Fonseca P, Gonzalez-Campora R, Gonzalez E, Cuatrecasas M, et al. Guidelines for biomarker testing in gastroenteropancreatic neuroendocrine neoplasms: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2014;16(3):243–56. https://doi.org/10.1007/s12094-013-1062-9.CrossRefPubMed

85.

Garcia-Carbonero R, JI-F P, Teule A, Barriuso J, Sevilla I, Spanish Society for Medical O. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014. Clin Transl Oncol. 2014;16(12):1025–34. https://doi.org/10.1007/s12094-014-1214-6.CrossRefPubMedPubMedCentral

86.

Riechelmann RP, Weschenfelder RF, Costa FP, Andrade AC, Osvaldt AB, Quidute AR, et al. Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group. Ecancermedicalscience. 2017;11:716. https://doi.org/10.3332/ecancer.2017.716.CrossRefPubMedPubMedCentral

87.

Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005;54(Suppl 4):iv1–16. https://doi.org/10.1136/gut.2004.053314.PubMedPubMedCentral

88.

Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012;61(1):6–32. https://doi.org/10.1136/gutjnl-2011-300831.CrossRefPubMed

89.

Inzani F, Petrone G, Fadda G, Rindi G. Cyto-histology in NET: what is necessary today and what is the future? Rev Endocr Metab Disord. 2017. https://doi.org/10.1007/s11154-017-9428-x.

90.

Fottner C, Ferrata M, Weber MW. Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose? Rev Endocr Metab Disord. 2017. https://doi.org/10.1007/s11154-017-9438-8.

91.

Castillo JG, Naib T, Zacks JS, Adams DH. Echocardiography in functional midgut neuroendocrine tumors: When and how often. Rev Endocr Metab Disord. 2017. https://doi.org/10.1007/s11154-017-9434-z.

92.

Alexandraki K, Angelousi A, Boutzios G, Kyriakopoulos G, Rontogianni D, Kaltsas G. Management of neuroendocrine tumors of unknown primary. Rev Endocr Metab Disord. 2017. https://doi.org/10.1007/s11154-017-9437-9.

93.

Ramirez RA, Chauhan A, Gimenez J, Thomas KEH, Kokodis I, Voros BA. Management of pulmonary neuroendocrine tumors. Rev Endocr Metab Disord. 2017. https://doi.org/10.1007/s11154-017-9429-9.

94.

Thomaschewski M, Neeff H, Keck T, Neumann HPH, Strate T, von Dobschuetz E. Is there any role for minimally invasive surgery in NET? Rev Endocr Metab Disord. 2017. https://doi.org/10.1007/s11154-017-9436-x.

95.

de Mestier L, Zappa M, Hentic O, Vilgrain V, Ruszniewski P. Liver transarterial embolizations in metastatic neuroendocrine tumors. Rev Endocr Metab Disord. 2017. https://doi.org/10.1007/s11154-017-9431-2.

96.

Sposito C, dit Busset MD, Citterio D, Bongini M, Mazzaferro V. The place of liver transplantation in the treatment of hepatic metastases from neuroendocrine tumors: Pros and cons. Rev Endocr Metab Disord. 2017. https://doi.org/10.1007/s11154-017-9439-7.

97.

Angelousi A, Kaltsas G, Koumarianou A, Weickert MO, Grossman A. Chemotherapy in NETs: When and how. Rev Endocr Metab Disord. 2017. https://doi.org/10.1007/s11154-017-9432-1.

98.

O’Shea T, Druce M. When should genetic testing be performed in patients with neuroendocrine tumours? Rev Endocr Metab Disord. 2017. https://doi.org/10.1007/s11154-017-9430-3.

99.

Amaral T, Leiter U, Garbe C. Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy. Rev Endocr Metab Disord. 2017. https://doi.org/10.1007/s11154-017-9433-0.

Title: Neuroendocrine neoplasms – still a challenge despite major advances in clinical care with the development of specialized guidelines
Authors: Stephan Petersenn
Christian A. Koch
Publication date: 01-12-2017
Publisher: Springer US
Published in: Reviews in Endocrine and Metabolic Disorders / Issue 4/2017
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-018-9442-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Neuroendocrine neoplasms – still a challenge despite major advances in clinical care with the development of specialized guidelines

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2017

Is there any role for minimally invasive surgery in NET?

Liver transarterial embolizations in metastatic neuroendocrine tumors

Cyto-histology in NET: what is necessary today and what is the future?

Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose?

When should genetic testing be performed in patients with neuroendocrine tumours?

Editorial

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page